| abstract |
The present invention provides changes in ERG gene expression. A method for detecting prostate cancer by examining the expression status of PSA / KLK3, PMEPA1 and ERG genes in a biological sample selected from serum, plasma, whole blood, urine and prostate fluid, comprising: Mixing a second oligonucleotide primer, wherein the first oligonucleotide primer comprises a sequence that hybridizes to a first sequence within a target sequence derived from ERG8, EPC1, or EPC2, and the second oligonucleotide primer comprises the target sequence Includes a sequence that hybridizes to the second sequence in the complementary nucleic acid strand to (b) thereby amplifying a plurality of amplification products (c) immobilizing the plurality of amplification products (d) oligonucleotide to the immobilized amplification product (E) Expression of the above gene and prostate cancer by detecting the signal from hybridization between the probe and amplification product It provides a way to indicate the presence. [Selection] Figure 9 |